Evidence map›Paper›PMID 41770935›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ42 fibrils with cross-seeding activity.

Katerina Konstantoulea, Meine Ramakers, Sarah C Borrie, Dries T'Syen, Daan Moechars, Malgorzata A Sliwinska, Brajabandhu Pradhan, Giulia Albertini, Nóra Baligács, Grigoria Tsaka and 10 more

Erratum issuedAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Katerina KonstantouleaSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0002-0960-6274
Meine RamakersSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0002-9417-4196
Sarah C BorrieSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0002-6880-772X
Dries T'SyenSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.
Daan MoecharsSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.
Malgorzata A SliwinskaSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0002-5016-4949
Brajabandhu PradhanSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.
Giulia AlbertiniSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.
Nóra BaligácsSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0002-2246-3669
Grigoria TsakaSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0002-8896-4191
Bert HoubenSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.
Mark FiersSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.
Rodrigo GallardoSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0003-1584-3564
Maarten DewildeLaboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven), Leuven, Flemish Brabant 3000, Belgium.ORCID 0000-0002-3138-281X
Dietmar Rudolf ThalUniversity of Leuven (KU Leuven), Leuven Brain Institute, Leuven 3000, Belgium.ORCID 0000-0002-1036-1075
Michael WillemBiomedical Center, Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich 82152, Germany.
Jonas J NeherBiomedical Center, Biochemistry, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich 82152, Germany.
Bart De StrooperSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0001-5455-5819
Frederic RousseauSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0002-9189-7399
Joost SchymkowitzSwitch Laboratory, VIB-KU Leuven Center for Neuroscience, VIB, Leuven 3000, Belgium.ORCID 0000-0003-2020-0168

Funding

Heterotypic amyloid interactions as modulators of selective cellular vulnerabilityR01AG079234 · NIA · FLANDERS INTERUNIV INST BIOTECHNOLOGY · PI Frederic Rousseau, Joost Schymkowitz · 2022 to 2026
$2.5M
Fonds Wetenschappelijk Onderzoek (FWO) 1223924 NFonds Wetenschappelijk Onderzoek (FWO) G0C3522NKU Leuven (Katholieke Universiteit Leuven) PDMT2/22/059National Institutes of Ageing, NIH R01AG079234NIA NIH HHS R01 AG079234Stichting Alzheimer Onderzoek Belgie 2020/0030
6 · The paper itself

Abstract

The prevailing view frames microglia and macrophages as guardians against amyloid beta (Aβ) accumulation in Alzheimer's disease (AD). Here, we overturn this paradigm by demonstrating that human phagocytic cells, including differentiated THP-1 macrophages and hESC-derived microglia, are not merely passive responders but active producers of extracellular, seeding-competent Aβ42 fibrils, the amyloid species most strongly linked to parenchymal plaque formation and neurodegeneration. These cell-generated aggregates differ structurally and functionally from synthetic fibrils, displaying enhanced seeding and tau cross-seeding activity in biosensor models. Notably, Aβ42 fibril formation in this system requires active cellular processes and is exacerbated by loss of Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), a major AD risk gene. Transcriptomic profiling reveals an early inflammatory response resembling microglial states observed in human AD models. Together, these findings support emerging evidence from in vivo studies that macrophages and microglia can influence amyloid seeding and introduce a human-relevant in vitro platform to explore how Aβ aggregation intersects with innate immune function and genetic risk. Our results reinforce the concept that microglia may play a dual role in AD, acting both as responders and inadvertent facilitators of amyloid assembly, with implications for early therapeutic intervention.

Indexed as

AmyloidAmyloid beta-PeptidesMacrophagesPeptide FragmentsPhagocytesPlaque, AmyloidAlzheimer DiseaseHumansMembrane GlycoproteinsMicrogliaReceptors, ImmunologicTHP-1 CellsAmyloidAmyloid beta-Peptidesamyloid beta-protein (1-42)Membrane GlycoproteinsPeptide FragmentsReceptors, ImmunologicTREM2 protein, humanAb42Alzheimer’s diseasemicrogliaTREM2

Identifiers

PMID41770935
PMCPMC12974450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.